J. Goldman & Co’s Biohaven Pharmaceutical Holding Company Ltd. BHVN Stock Holding History

J. Goldman & Co’s Portfolio BHVN Stock Details BHVN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-20,096	Closed	-$2.79M	–	501
2021 Q3	$2.79M	Buy	+20,096	New	+$2.51M	0.14%	165
2019 Q3	–	Sell	-10,000	Closed	-$438K	–	425
2019 Q2	$438K	Buy	10,000 +931	+10%	+$52.5K	0.03%	228
2019 Q1	$467K	Buy	9,069 +3,059	+51%	+$132K	0.03%	238
2018 Q4	$222K	Sell	6,010 -20,478	-77%	-$738K	0.02%	220
2018 Q3	$995K	Buy	26,488 +16,120	+155%	+$593K	0.07%	189
2018 Q2	$410K	Sell	10,368 -101,623	-91%	-$3.22M	0.02%	296
2018 Q1	$2.88M	Buy	111,991 +104,794	+1,456%	+$3.13M	0.12%	183
2017 Q4	$194K	Buy	+7,197	New	+$198K	0.01%	299

Other funds holding BHVN

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Stifel Financial St. Louis, Missouri $109B AUM 21.36% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

OIM

Oracle Investment Management Greenwich, Connecticut $168M AUM 42.86% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

Allspring Global Investments Charlotte, North Carolina $59.7B AUM 29.08% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

J. Goldman & Co's BHVN Position: Q4 2021 in Review

J. Goldman & Co sold out of Biohaven Pharmaceutical Holding Company Ltd. (BHVN) in Q4 2021, closing a stake of 20,096 shares — an estimated $2.79M sold.

J. Goldman & Co first reported a position in BHVN in Q4 2017 and held it in 8 quarters. The position peaked at $2.88M in Q1 2018. 284 funds tracked by Wall St. Rank hold BHVN as of Q4 2021.

J. Goldman & Co reported no remaining Biohaven Pharmaceutical Holding Company Ltd. position as of Q4 2021 after selling out during the quarter.
J. Goldman & Co sold 20,096 Biohaven Pharmaceutical Holding Company Ltd. shares in Q4 2021, an estimated $2.79M.
J. Goldman & Co first reported a position in Biohaven Pharmaceutical Holding Company Ltd. in Q4 2017 and held it in 8 quarters.
J. Goldman & Co's Biohaven Pharmaceutical Holding Company Ltd. position peaked at $2.88M in Q1 2018.
284 funds tracked by Wall St. Rank held Biohaven Pharmaceutical Holding Company Ltd. as of Q4 2021.

Based on J. Goldman & Co's 13F filing for Q4 2021, filed 14 Feb 2022.